A novel drug alleviated inflammation and symptoms of eosinophilic gastritis and eosinophilic duodenitis in a randomized, double-blind trial. Antolimab (Allakos), a monoclonal antibody targeting siglec-8, is on track to become the first therapy indicated for eosinophilia below the esophagus in the GI tract.
In the phase 2 study, called ENIGMA, antolimab “met all prespecified end points, demonstrating significant histologic and symptomatic improvement,” Evan S. Dellon, MD, a professor